Teva, the world's largest generic medicines group, on Tuesday signalled its ambitions to dominate the growing market for copies of off-patent biological drugs by joining forces with Switzerland’s Lonza.

Shlomo Yanai, head of Israel-based Teva, said the partnership would compete on eight of the top-selling ten biological medicines coming off patent over the next decade, which between them are currently generating annual sales $30bn.